In plain language
Liraglutide is a daily injectable medicine that mimics the gut hormone GLP-1 to help control blood sugar and reduce appetite. It is FDA-approved for type 2 diabetes and for weight management, supported by large human trials. It is prescription-only.
What it is explored for
Liraglutide is one of the longer-established GLP-1 medicines, FDA-approved for both type 2 diabetes and weight management and backed by years of human trial data. Its daily dosing gives clinicians a smoother, more adjustable option, and researchers continue to explore its wider metabolic value.
- Weight management (FDA-approved)
- Blood sugar control in type 2 diabetes (FDA-approved)
- Appetite regulation and reduced food intake
- Cardiovascular benefit demonstrated in outcome trials
- Flexible daily titration for sensitive patients
- Explored for PCOS (off-label, growing evidence)
These are areas of active interest and reported use, not proven outcomes. This peptide carries a strong (human) rating, see the evidence summary below for how strong the science actually is.
How it works
Liraglutide is a GLP-1 analog with a fatty-acid modification that extends its half-life to allow once-daily dosing. It activates the GLP-1 receptor.
- Glucose-dependent insulin release. Promotes insulin secretion when blood glucose is elevated, with low hypoglycemia risk on its own.
- Appetite and satiety. Acts on appetite-regulating brain regions and slows gastric emptying, reducing food intake.
- Glucagon suppression. Lowers post-meal glucagon, helping reduce excess glucose output from the liver.
These mechanisms are established in humans through large clinical trials and regulatory review.
Evidence summary
Liraglutide has strong human evidence from the LEAD program for diabetes, the SCALE program for weight management, and the LEADER cardiovascular outcomes trial, which showed reduced major cardiovascular events in people with type 2 diabetes. It is a long-established, approved medicine.
Reported safety & side effects
Common side effects are gastrointestinal (nausea, diarrhea, vomiting), often strongest during dose escalation. It carries a boxed warning about thyroid C-cell tumors based on rodent data and is used under medical supervision.
Stacking notes
Full stacking guideDo not stack two incretin agonists (for example semaglutide with tirzepatide, or with liraglutide). They act on the same pathway, so side effects like nausea, vomiting, and dehydration add up while there is no evidence of extra benefit. Switch between them under medical care rather than combining.
SemaglutideTirzepatideGeneral educational guidance, not medical advice. Combination evidence is limited; any stack should involve a qualified clinician.
Frequently asked
Is liraglutide FDA-approved?
Yes. It is approved as Victoza for type 2 diabetes and as Saxenda for chronic weight management. It is prescription-only.
How is it different from semaglutide?
Liraglutide is dosed once daily and is an older GLP-1 agonist, while semaglutide is dosed weekly and has shown larger average weight and HbA1c reductions in trials. Both are approved and effective.
How often is it injected?
Liraglutide is taken as a once-daily subcutaneous injection.